Abstract: A position encoder comprises: a first and second member, with the first member movable relative to the second member; a first sensor arranged at one of the first or second members, and a first track arranged at the other one of the first or second members such that the first sensor moves along the first track when the first member moves relative to the second member, with the first sensor capturing at least one of its position or displacement along the first track; a second sensor arranged at one of the first or second members, and a second track arranged at the other one of the first or second members such that the second sensor moves along the second track when the first member moves relative to the second member, with the second sensor capturing at least one of its position or displacement along the second track.

Abstract: The present invention relates to humanized antibodies that specifically hind to human transferrin receptor and their use in treating cancer and inflammatory disorders.

Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.

Abstract: The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to TfR, the transferrin receptor, and wherein the drug is preferably chosen among a cytotoxic drug. Such antibody-drug conjugates are useful in particular in treating proliferative diseases including cancers, such as lymphoma or leukaemia.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The CD71 receptor is used as a target in the prognosis and/or treatment of endometriosis, and to a test for the prognosis or therapeutic monitoring of endometriosis, targeting this receptor.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO:1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to humanized antibodies that specifically bind to human transferrin receptor and their use in treating cancer and inflammatory disorders.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the Fc?RI receptor for the treatment of inflammatory diseases.

Abstract: The invention relates to the use of a monovalent antibody fragment directed against the EC2 domain of the Fc?RI receptor for the treatment of inflammatory diseases.

Abstract: Differentially expressed L-type calcium channel nucleic acid sequences and polypeptides have been identified that include novel sequences that are differentially expressed in non-excitable cells. Such sequences can be used, for example, as targets for identifying agents that modulate calcium influx, e.g., in non-excitable cells. Methods related to modulation of cell growth are also included.

Abstract: Machine for monitoring internal equipment of a nuclear reactor, when stored outside the reactor vessel in the swimming pool of the reactor, comprising a first longitudinal carriage (16) movable on rails (14) on the bottom of the swimming pool, a transverse beam (46) movable on the first carriage (16), a second transverse carriage (61) bearing monitoring instruments (65) and movable on the beam (46), and an arrangement for moving the beam (46) in predetermined steps on the first carriage (16), and the second carriage (61) on the beam (46).